115 related articles for article (PubMed ID: 37130350)
1. Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance.
He P; Feng J; Xia X; Sun Y; He J; Guan T; Peng Y; Zhang X; Liu M; Pang X; Chen Y
J Med Chem; 2023 May; 66(9):6047-6069. PubMed ID: 37130350
[TBL] [Abstract][Full Text] [Related]
2. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
4. OXPHOS-targeting drugs in oncology: new perspectives.
Kalyanaraman B; Cheng G; Hardy M; You M
Expert Opin Ther Targets; 2023; 27(10):939-952. PubMed ID: 37736880
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
[TBL] [Abstract][Full Text] [Related]
6. SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation.
Xiang Y; Fang B; Liu Y; Yan S; Cao D; Mei H; Wang Q; Hu Y; Guo T
Life Sci; 2020 Sep; 256():117971. PubMed ID: 32553925
[TBL] [Abstract][Full Text] [Related]
7. Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in
Feng J; Lian Z; Xia X; Lu Y; Hu K; Zhang Y; Liu Y; Hu L; Yuan K; Sun Z; Pang X
Acta Pharm Sin B; 2023 Mar; 13(3):1145-1163. PubMed ID: 36970205
[TBL] [Abstract][Full Text] [Related]
8. Cyclopamine tartrate, a modulator of hedgehog signaling and mitochondrial respiration, effectively arrests lung tumor growth and progression.
Kalainayakan SP; Ghosh P; Dey S; Fitzgerald KE; Sohoni S; Konduri PC; Garrossian M; Liu L; Zhang L
Sci Rep; 2019 Feb; 9(1):1405. PubMed ID: 30723259
[TBL] [Abstract][Full Text] [Related]
9. Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer.
Masoud R; Reyes-Castellanos G; Lac S; Garcia J; Dou S; Shintu L; Abdel Hadi N; Gicquel T; El Kaoutari A; Diémé B; Tranchida F; Cormareche L; Borge L; Gayet O; Pasquier E; Dusetti N; Iovanna J; Carrier A
Cell Rep Med; 2020 Nov; 1(8):100143. PubMed ID: 33294863
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
12. Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation.
Cheng G; Hardy M; You M; Kalyanaraman B
Sci Rep; 2022 Mar; 12(1):5143. PubMed ID: 35332210
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
Baek ML; Lee J; Pendleton KE; Berner MJ; Goff EB; Tan L; Martinez SA; Mahmud I; Wang T; Meyer MD; Lim B; Barrish JP; Porter W; Lorenzi PL; Echeverria GV
Oncogene; 2023 Mar; 42(14):1117-1131. PubMed ID: 36813854
[TBL] [Abstract][Full Text] [Related]
15. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
[TBL] [Abstract][Full Text] [Related]
16. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers.
Chen CL; Lin CY; Kung HJ
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948229
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
19. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.
Valenti D; de Bari L; Manente GA; Rossi L; Mutti L; Moro L; Vacca RA
Biochim Biophys Acta; 2013 Dec; 1832(12):2085-96. PubMed ID: 23911347
[TBL] [Abstract][Full Text] [Related]
20. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
